Cell therapy for DLL3-positive small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new cell therapy called TC-D101 for people with a type of small cell lung cancer that has DLL3 protein on its surface. It may be an option if standard treatments have stopped working or are not suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be between 18 and 75 years old.
- Your cancer must have a specific protein called DLL3, confirmed by a lab test.
- Standard treatments for your lung cancer have failed or are not an option for you.
- Your overall health must be good (able to do daily activities with little or no help).
- Your kidneys, liver, bone marrow, and other organs must be working well enough.
- You need to have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
This trial tests a new type of immunotherapy called dual-target CAR-NK cells for people with small cell lung cancer that has returned or not responded to treatment. The treatment uses your own immune cells, modified in a lab, to better recognize and attack cancer cells.
This trial tests a new cell therapy that uses your own immune cells to attack cancer. It's for people with small cell lung cancer that has come back or not responded to standard treatments.
This trial uses a special PET/CT scan to look for a protein called DLL3 in small cell lung cancer. The scan may help doctors better see and understand the cancer. You may be able to join if you have suspected or confirmed small cell lung cancer and certain blood markers are high.
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.